A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

NCT03343054 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer